Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709607 | 0.92 | MAPT (0.55) | REN | |
| SCHEMBL5709664 | 0.87 | REN (0.51) | REN | |
| SCHEMBL7345581 | 0.82 | REN (0.50) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9583268 | 0.82 | REN (0.45) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5709565 | 0.78 | REN (0.62) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9249864 | 0.78 | REN (0.62) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5709639 | 0.78 | REN (0.45) | REN | |
| SCHEMBL5709601 | 0.77 | REN (0.54) | REN | |
| SCHEMBL5709600 | 0.77 | REN (0.66) | REN | |
| SCHEMBL5709640 | 0.75 | REN (0.55) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | claimed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| EP-0431520-B1 | Heterocyclic acyl aminodiol beta-amino acid derivatives | SEARLE & CO (US) | 1995-02-08 | — | — | EP | disclosed |
| US-5283250-A | Renin inhibitor;hypotensive agent | G. D. SEARLE & CO. (US) | 1994-02-01 | — | — | US | disclosed |
| US-5231111-A | Imidazolyl/imidazolylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives | G. D. SEARLE & CO. (US) | 1993-07-27 | — | — | US | disclosed |
| US-5223532-A | Chromonyl/chromonylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino derivatives | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | disclosed |
| US-5223514-A | Renin inhibiros, hypotensive agents | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | disclosed |
| US-5217991-A | Renin inhibitors for treating hypertension | G. D. SEARLE & CO. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5217989-A | Benothiophenyl/benzothiophenylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives | G. D. SEARLE & CO. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5212174-A | Renin inhibitors for hypotensive agents | G. D. SEARLE & CO. (US) | 1993-05-18 | — | — | US | disclosed |
| US-5212175-A | Benzothiophenyl benzothiophenylalkyl-N-terminal amino hydroxy β-amino acid derivatives | G. D. SEARLE & CO. (US) | 1993-05-18 | — | — | US | disclosed |
| US-5180725-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1993-01-19 | — | — | US | disclosed |
| US-5180744-A | Renin inhibitors; hypotensive agents | G. D. SEARLE & CO. (US) | 1993-01-19 | — | — | US | disclosed |
| US-5179102-A | Naphthyridinyl/naphthyridinylalkyl-n-terminal anino hydroxy β-amino acid derivatives | G. D. SEARLE & CO. (US) | 1993-01-12 | — | — | US | disclosed |
| US-5175181-A | Renin inhibitors, hypotensive agents | G. D. SEARLE & CO. (US) | 1992-12-29 | — | — | US | disclosed |
| US-5175170-A | Renin inhibitors, hypotensive agents | G. D. SEARLE & CO. (US) | 1992-12-29 | — | — | US | disclosed |
| US-5147888-A | Hypotensive agents; renin inhibitors | G. D. SEARLE & CO. (US) | 1992-09-15 | — | — | US | disclosed |
| EP-0431520-A2 | Heterocyclic acyl aminodiol beta-amino acid derivatives | G.D. Searle & Co. (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | REN 2199/4885PSEN1 5/4885PSEN2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.